Treating sepsis with a medication plus blood thinner
Part of Infections clinical trials.
This trial studies whether combining anisodamine (a medicine for certain gut/smooth-muscle effects) with a low-molecular-weight blood thinner helps treat sepsis. It may be aimed at improving outcomes compared with standard care, but eligibility depends on safety factors like bleeding risk and organ function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be over 18 years old.
- You must meet the study’s sepsis diagnosis criteria (Sepsis-3).
- You (or a legal representative) must be able to agree to participate and sign consent.
- You should not be expected to die within 24 hours after starting the study.
- You must not have a known reason you cannot safely take the blood thinner or anisodamine (scopolamine butylbromide).
- You must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medication called anisodamine to see if it can improve blood flow in tiny blood vessels under the tongue in people with septic shock. This might help their organs work better and make them recover faster.
This study tests a new medicine called BAY 3389934 to see if it's safe and what dose works best for people with sepsis and blood clotting issues. The goal is to improve blood clotting and help you recover from the infection.
This trial tests if the oral medication midodrine can help wean patients with sepsis off IV vasopressors faster, potentially reducing ICU stays and complications.
This trial tests a new treatment to protect and repair the layer of cells lining your blood vessels (glycocalyx) during sepsis. It aims to improve recovery from severe infections.
This trial looks at whether a blood-filter treatment (called “AN69ST Verse PS” using a hemofilter) can help children with early, serious sepsis and poor circulation or organ problems. It may help stabilize the body faster, but eligibility is limited to certain sepsis situations and recent timing.
This study tests whether giving an early antibiotic (meropenem) based on a new blood test (PSP) can prevent serious infections (sepsis) in people who come to the emergency department with signs of infection. The goal is to find out if this approach helps them get better faster and avoid more severe illness.
Hear when a new Sepsis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.